Last reviewed · How we verify
WPV01 Dose 9-12
WPV01 is a novel small molecule drug developed by Westlake Pharmaceuticals, currently in early clinical development. It has completed a Phase 1 study in healthy subjects, showing promising safety and pharmacokinetic profiles. Further clinical trials are needed to evaluate its efficacy in specific indications.
At a glance
| Generic name | WPV01 Dose 9-12 |
|---|---|
| Sponsor | Westlake Pharmaceuticals (Hangzhou) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WPV01 Dose 9-12 CI brief — competitive landscape report
- WPV01 Dose 9-12 updates RSS · CI watch RSS
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd. portfolio CI